Mohammed Khoso Baluch
Chairman chez POXEL
Fortune : 7 369 $ au 31/03/2024
Profil
Mohammed Khoso Baluch currently works at Poxel SA, as Chairman from 2023, Longeveron, Inc., as Independent Director from 2023, and Processa Pharmaceuticals, Inc., as Independent Director from 2022.
Mr. Baluch also formerly worked at CorMedix, Inc., as Chief Executive Officer & Director from 2020 to 2021, UCB Pharma AS, as Chairman, Da Volterra SA, as Chairman from 2021 to 2022, UCB Pharma AB, as Chairman, UCB Pharma Sp zoo, as Chairman-Management Board, UCB AE, as Chairman, JDRF International, as Director-Indiana Chapter, UCB, Inc., as Director & Senior VP & President-Europe Region from 2008 to 2016, Juvenile Diabetes Research Foundation of Arizona, Inc., as Director, UCB Pharma Ltd., as Director, Eli Lilly & Co., as VP-US Diabetes & Family Health Business Unit from 2002 to 2008, UCB SA, as Senior VP & President-EMEA Region from 2015 to 2016, UCB Pharma SA, as Manager, and Vedim Pharma SA, as Manager.
Mr. Baluch received his undergraduate degree from City University London and Masters Business Admin degree from Cranfield School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LONGEVERON INC. CLASS A
0,12% | 16/02/2024 | 1 250 ( 0,12% ) | 4 063 $ | 31/03/2024 |
| 01/09/2023 | 1 398 ( 0,08% ) | 3 306 $ | 31/03/2024 |
Postes actifs de Mohammed Khoso Baluch
| Sociétés | Poste | Début |
|---|---|---|
| POXEL | Chairman | 01/03/2023 |
| PROCESSA PHARMACEUTICALS, INC. | Director/Board Member | 11/07/2022 |
| LONGEVERON INC. | Director/Board Member | 09/06/2023 |
Anciens postes connus de Mohammed Khoso Baluch
| Sociétés | Poste | Fin |
|---|---|---|
Da Volterra SA
 Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | Chairman | 01/11/2022 |
| CORMEDIX INC. | Chief Executive Officer | 04/10/2021 |
| UCB | Corporate Officer/Principal | 01/04/2016 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Director/Board Member | 01/01/2016 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/07/2008 |
Formation de Mohammed Khoso Baluch
| City University London | Undergraduate Degree |
| Cranfield School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CORMEDIX INC. | Health Technology |
| POXEL | Health Technology |
| UCB | Health Technology |
| LONGEVERON INC. | Health Technology |
| PROCESSA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
UCB Pharma SA
 UCB Pharma SA Chemicals: SpecialtyProcess Industries UCB Pharma SA manufactures pharmaceutical products. It develops products in areas, such as epilepsy, central nervous system, immunology and inflammation. The company is headquartered in Molins de Rei, Spain | Process Industries |
JDRF International
 JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Vedim Pharma SA
 Vedim Pharma SA Pharmaceuticals: MajorHealth Technology Part of UCB SA, Vedim Pharma SA is a French pharmaceutical company that manufactures pharmaceuticals. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
| UCB Pharma AS | |
Da Volterra SA
Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | Health Technology |
| Juvenile Diabetes Research Foundation of Arizona, Inc. | |
UCB Pharma Ltd.
 UCB Pharma Ltd. Pharmaceuticals: MajorHealth Technology UCB Pharma Ltd. operates as a biopharmaceutical company. The firm focuses on developing medicines for severe diseases in Immunology and CNS. The company is headquartered in Slough, the United Kingdom. | Health Technology |
| UCB Pharma AB | |
| UCB Pharma Sp zoo | |
| UCB AE |
